Our impact
Investment in the Catapult network, by Innovate UK, is an economic initiative and we have a clear model for achieving and demonstrating economic impact.

It is our mandate to catalyse and facilitate growth in the cell and gene therapy industry. Since our inception in 2012, we have been gathering qualitative and quantitative data to showcase the impact we are having on the companies and researchers we work with and on general industry growth.

UK companies have received

There are
ATMP developers in the UK compared to 22 in 2012

Of UK ATMP developers
are collaborating with CGT Catapult

There are
active clinical trials in 2019, compared to 85 in 2018

There has been
growth in UK clinical trials

There are
jobs compared to 540 in 2012

There are
GMP facilities compared to 11 in 2012

There has been
increase in the number of GMP manufacturing facilities

CGT Catapult manufacturing centre opened in 2018

  • RT : I am delighted to announce new Life Science Opportunity Zones which will boost this important thriving sector. The… https://t.co/4aKZVaZqgE 1 day 9 hours ago

Discover who we are